- Presents a 6-step process that makes building drug budget-impact analyses easy to understand
- Detailed descriptions of analytic framework components facilitate the building of analyses customized for specific jurisdictions
- A computing framework enables the reader to differentiate between a static and dynamic approach to budget-impact analysis and identify when each is the appropriate option
- Exercises associated with each chapter allow the reader to apply the material presented to real-life issues in building budget-impact analyses
The first of its kind for budget-impact analysis, this comprehensive guide provides clear and concise instructions for evaluating the impact that new pharmaceuticals will have on the budget for a specific jurisdiction. The book demonstrates how to create a budget-impact analysis using a simple six-step process that is consistent with current guidelines for these analyses. Examples and exercises for each chapter afford an opportunity to practice the six-step process in practical applications.
The book progresses from a framework for budget impact analyses to an in-depth review of components and how to develop and present these in software applications and reports. Critical considerations such as uncertainty analysis and validation, and considerationsfor alternate interventions, such as vaccines and diagnostics, are also covered.
This book is a “must have” for the builder and budget holder, with builders benefiting from instructions to identify and estimate all necessary variables and budget holders receiving a guide to what should be included in the analyses they assess.
Josephine A. Mauskopf, PhD, MHA, MA
Josephine Mauskopf is Vice President of Health Economics at RTI Health Solutions. She has been on the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Board of Directors and was co-chair of the first and second ISPOR Task Force for budget-impactanalysis. Dr. Mauskopf was Department Head of Economics Research at Burroughs Wellcome Co. and Director of Pharmacoeconomics Research for Anti-Virals and Anti-Infectives at Glaxo Wellcome Inc.
Her research interest is in designing and implementing pharmacoeconomic research strategies and programs for the pharmaceutical industry.
She has published over 100 articles and written an encyclopedia entry for budget-impact analysis. She has served as Editor-in-Chief of Value in Health and is an Associate Editor for Medical Decision Making. Dr. Mauskopf was also the recipient of the 2013 Avedis DonabedianLifetime Achievement Award.
Stephanie R. Earnshaw, PhD, MS
Stephanie Earnshaw is Senior Vice President of Health Economics at RTI Health Solutions. She has also had an adjunct professor appointment in the University of North Carolina (UNC) Eshelman School of Pharmacy, Division of Pharmaceutical Outcomes and Policy. Prior to joining RTI Health Solutions, Dr. Earnshaw worked in UNC’s School of Public Health as the Operations Director of the Survey Research Unit and taught courses in the Kenan-Flagler Business School.
Her research interest is primarily in applying decision analytic techniques to novel pharmacoeconomic and outcomes research problems for the pharmaceutical industry.
She has published 47 articles and has written 3 book chapters. She has taught short courses and distance learning courses for the International Society for Pharmacoeconomics and Outcome Research and is on the editorial board of PharmacoEconomics – Open.